(lp0
S'Curis to Present at the Oppenheimer &amp; Co. Inc. 27th Annual Healthcare Conference GlobeNewswire  - Mar 16, 2017 LEXINGTON, Mass., March 16, 2017  -- March 16, 2017 - Curis, Inc. , a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today&nbsp;...'
p1
aS"Curis Dares To Be Different Seeking Alpha - Mar 28, 2017 To borrow a phrase from Chuck Palahniuk, the first rule of Curis  Club is: Don't be entirely dependent on Erivedge royalties."
p2
aS'Curis May Make A Splash In Immune Checkpoint Inhibition Seeking Alpha - Jun 21, 2016 Curis, Inc. is a developmental biotech with one approved drug and an investigational agent in phase 2 clinical trials.'
p3
aS'Curis, Inc.  Could Reverse On Near Term Catalysts Insider Financial - Jul 22, 2016 Massachusetts based biotech Curis, Inc.  soared into the close of 2015, as data from its lead oncology candidate hinted at a revolution in cancer therapy.'
p4
aS"Curis: One Swallow Doesn't Make A Summer Seeking Alpha - Nov 22, 2016 Curis Therapeutics   was incorporated on February 14, 2000 and trades on the Nasdaq Global Market. Headquartered in Lexington, Massachusetts, it is a clinical-stage biopharmaceutical company engaged in developing and&nbsp;..."
p5
aS'Curis Inc.  Plunges 7.94% on April 05 Equities.com - Apr 5, 2017 Curis Inc.  had a rough trading day for Wednesday April 05 as shares tumbled 7.94%, or a loss of $-0.22 per share, to close at $2.55.Curis, Inc.  Analyst Opinion And Outlook - Post AnalystCuris, Inc.  Upgraded at Zacks Investment Research - Sports Perspectives'
p6
aS'Curis to Present at the 2017 RBC Capital Markets Global Healthcare Conference GlobeNewswire  - Feb 17, 2017 LEXINGTON, Mass., Feb. 17, 2017  -- Curis, Inc. , a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that&nbsp;...'
p7
aS'Curis, Inc.  recently purchased by insider Aurigene Discovery ... Post Analyst - 20 hours ago Curis, Inc.  reached 73.47% versus a 1-year low price of $1.47. The stock was last seen 1.19% higher, reaching at $2.55 on Apr. 13, 2017.Curis, Inc.  Earns &quot;Buy&quot; Rating from Cowen and Company - Community Financial NewsThe Curis, Inc.  Given Consensus Rating of Buy by Analysts - Petro Global News 24'
p8
aS'Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision ... GlobeNewswire  - Jan 9, 2017 LEXINGTON, Mass., Jan. 09, 2017  -- Curis, Inc. , a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today announced that&nbsp;...'
p9
aS'Curis, Inc.  Reaches $2.62 After 6.00% Up Move, Compania Cervecerias ... Key Gazette - 17 hours ago Among 4 analysts covering United Breweries Company Limited , 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive.'
p10
a.